# One-Page Investor Summary (with Aims)

## Vision
GenomeLTM-MoE is a research-first genomics AI platform that turns raw sequencing reads from multiple technologies into calibrated, evidence-grounded genome interpretations. The system is built to reduce false confidence, resolve disagreement between sequencing platforms, and make results auditable for biomedical research.

## The problem
Today’s genomic pipelines often produce definitive outputs even when evidence is ambiguous (repeats, SV breakpoints, immune regions). This can mislead downstream research and inflate confidence in uncertain claims. Long-read adoption helps, but integrating multiple technologies remains complex and inconsistent.

## Our solution
A hierarchical, ultra-long-context model with:
- FASTQ-first noise-aware representation learning
- Mixture-of-Experts specialization for hard regions and event types
- A verifier/judge loop that re-checks low-confidence outputs and can abstain
- Cross-technology consensus (Illumina + PacBio + ONT)
- Standards-compliant outputs (VCF v4.3 + evidence extensions)

## Differentiation
- Evidence-aware and uncertainty-first (abstention + ambiguity modeling)
- Multi-tech consensus as a core feature (not an afterthought)
- Designed for publishable benchmarking and reproducibility

## Initial markets (research-first, then translation)
- Academic labs: variant interpretation and difficult-region analysis
- Biotech/pharma: cohort stratification, target/variant prioritization
- Sequencing service providers: cross-platform QA and consensus pipelines

## Aims (12–18 months)
**Aim 1 — Calibrated variant and SV evidence from raw reads**
Deliver a validated pipeline that outputs calibrated posteriors and identifies ambiguous regions reliably, with reproducible benchmarks.

**Aim 2 — Multi-technology consensus engine**
Demonstrate measurable improvements in concordance and reduced false positives by fusing Illumina + long-read evidence with explicit conflict handling.

**Aim 3 — Publishable evaluation suite and open research tooling**
Release a robust benchmark harness (calibration, risk-coverage curves, SV breakpoints, cross-tech ablations) and submit a paper describing the system.

## Milestones
- M1 (0–3 mo): infrastructure + Stage 1 denoising prototype, profiling
- M2 (3–6 mo): tile memory + cross-tech alignment + baseline heads
- M3 (6–12 mo): verifier + abstention policy + full benchmark suite
- M4 (12–18 mo): paper submission + partner pilots (academic/biotech)

## Compute & budget narrative
Start with targeted prototype runs, then scale. Costs are controlled via:
- staged curriculum (only scale when metrics improve)
- selective compute (MoE routing + retrieval)
- explicit abstention (avoid overfitting to uncertain regions)

## Team needs
- ML systems engineer (distributed training/MoE)
- Genomics scientist (benchmarks, truth sets, failure analysis)
- Security/privacy advisor for any human genomic data handling

## Risk & mitigation
- Risk: dataset bias → mitigate via ancestry/platform diversity + calibration reporting
- Risk: overconfidence → mitigate via abstention-first design + verifier auditing
- Risk: compute overruns → mitigate via curriculum gates and profiling-first scaling
